By evaluating multiple biomarkers of cardiovascular stress, Sabatine et al. [35] found that the approach helped to select those patients with stable coronary disease who were at a higher possibility of heart failure and cardiovascular death, which may be beneficial for identifying patients who obtain compelling advantages from angiotensin-converting enzyme inhibitor treatment. Here, ACE is linked to heart failure.